- Oops!Something went wrong.Please try again later.
The data will be presented at the upcoming European Hematology Association (EHA) Virtual Congress 2021.
No severe/life-threatening treatment-related adverse events nor evidence of Graft-versus-Host disease were reported from the completed first dose-level (DL1) cohort of the trial.
Initial results at a low dose of 30x106 cells per infusion showed preliminary signs of clinical activity, including a confirmed partial response.
CYAD-211 is an investigational, non-gene edited allogeneic CAR T candidate engineered to co-express a single hairpin RNA (shRNA) and a BCMA-targeting chimeric antigen receptor.
Price Action: CYAD shares are trading 21.9% higher at $6.47 during the premarket session on the last check Thursday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.